Safety and PK of LY3541860 in Healthy Participants

Phase 1, randomised, double-blind trial of LY3541860 in rheumatoid arthritis (RA) and multiple sclerosis (MS) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2021; status: completed.